Post Profile






Regeneron's Eylea combination therapy fails mid-stage study

(Reuters) - Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug, Eylea, was inferior to Eylea alone in a mid-stage trial involving patients with wet age-related macular degeneration (AMD), a leading cause of blindness in the elderly.
read more

share
See more about: Regeneron Pharmaceuticals

Related Posts


Regeneron And Bayer Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion

Health : Medical News Today

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central r...

FDA Grants Priority Review For VEGF Trap-Eye For The Treatment Of Wet Age-Related Macular Degeneration

Health : Medical News Today

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for VEGF Trap-Eye for the treatment of the neovascul...

FDA Schedules Advisory Committee Meeting To Discuss BLA For VEGF Trap-Eye For The Treatment Of Wet Age-Related Macular Degeneration

Health : Medical News Today

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that the U.S. Food and Drug Administration (FDA) has informed the company that it has scheduled a Dermatologic and Ophthalmic Drugs Advisory Committee Meeting to be held on Ju...

Regeneron Pharmaceuticals Inc (REGN), Ampio Pharmaceuticals, Inc. (AMPE): Is This Eye Drug Worth The Hype?

Business & Finance / Investing : Insider Monkey

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) should spike– every time there’s a slight pullback the stock shoots higher. Last Thursday Regeneron gained almost 10% behind a positive Phase 3 trial for its drug Eylea. Regeneron Pharmace...

Regeneron Announces EYLEA™ (aflibercept Ophthalmic Solution) Receives Unanimous Recommendation For Approval For Treatment Of Wet AMD From FDA

Health : Medical News Today

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that the Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted unanimously to recommend that the FDA approve EYLEA™, al...

Comments


Copyright © 2016 Regator, LLC